Patents Examined by Yong Chu
  • Patent number: 8101781
    Abstract: The present invention relates to a process for the efficient preparation of highly optical pure chiral carvedilol. According to the present invention, a chiral oxazolidin-2-one or oxazolidin-2-thione having formula 2, produced from the reaction of N-protected 2-(2-methoxyphenoxy)ethylamine with a chiral glycidol derivative is used as a key intermediate for the preparation of the chiral carvedilol. Specifically, the process for the preparation of the chiral carvedilol comprises a) reacting a compound of formula 2 with a halogenation agent, a sulfonation agent or a mitsunobu reagent to activate a hydroxyl group of the compound of formula 2, followed by nucleophilic substitution reaction with 9H-4-hydroxy carbazole to produce a compound of formula 7, and b) subjecting the obtained compound of formula 7 to a deprotection reaction in a presence of an inorganic base to produce the targeted chiral carvedilol. The process of the present invention can be accomplished in a mild condition.
    Type: Grant
    Filed: August 31, 2006
    Date of Patent: January 24, 2012
    Assignees: AHN-Gook Pharmaceutical Co., Ltd., RSTech Corporation
    Inventors: Seong-Jin Kim, Chang Woo Jong, Hyun Bin Kang, Byung Hyun Moon, Long Guo Quan, Duk Kwon Won, Kyung Yong Jin
  • Patent number: 8101646
    Abstract: In illustrative embodiments, there is provided an amorphous form of L-arginine salt of perindopril which may be particularly suitable for pharmaceutical applications, and processes for preparing said form.
    Type: Grant
    Filed: September 3, 2009
    Date of Patent: January 24, 2012
    Assignee: Apotex Pharmachem Inc.
    Inventors: Gamini Weeratunga, Carlos B. Zetina-Rocha
  • Patent number: 8101749
    Abstract: The invention relates to a method for producing onium salts with tetrafluoroborate anion by reacting an onium halide with an oxonium tetrafluoroborate, sulfonium tetrafluoroborate, or triphenylcarbonium tetrafluoroborate.
    Type: Grant
    Filed: November 18, 2005
    Date of Patent: January 24, 2012
    Assignee: Merck Patent Gesellschaft mit beschrankter Haftung
    Inventors: Nikolai (Mykola) Ignatyev, Urs Welz-Biermann, Andriy Kucheryna, Helge Willner
  • Patent number: 8097654
    Abstract: The present invention provides a radiolabeled ligand which is highly selective and potent for glutamate transporters and is usable in specifically detecting the glutamate transporter. Specifically, the present invention provides a 3-[3-(benzoylamido)benzyloxy]aspartic acid having a radioactive substituent on the benzoyl group which is represented by the following formula (1), or an ester or salt thereof: wherein X represents a substituent containing a radioactive atom(s) which is selected from a straight or branched lower aliphatic alkyl group, a hydroxyl group, a straight or branched lower aliphatic alkoxy group, an amino group, a straight or branched lower aliphatic acylamido group, a halogen atom and a straight or branched lower aliphatic haloalkyl group; and R1 and R2 each represents a hydrogen atom, a straight or branched lower aliphatic alkyl group or an acetoxymethyl group.
    Type: Grant
    Filed: March 18, 2005
    Date of Patent: January 17, 2012
    Assignee: Suntory Holdings Limited
    Inventors: Keiko Shimamoto, Hideo Saji, Yuji Kuge, Masashi Ueda, Masamichi Satoh, Takayuki Nakagawa
  • Patent number: 8093404
    Abstract: Chemically reactive carbocyanine dyes that are intramolecularly crosslinked between the 1-position and 3?-position, their bioconjugates and their uses are described. 1,3?-crosslinked carbocyanines are superior to those of conjugates of spectrally similar 1,1?-crosslinked or non-crosslinked dyes. The invention includes derivative compounds having one or more benzo nitrogens.
    Type: Grant
    Filed: August 20, 2009
    Date of Patent: January 10, 2012
    Assignee: AnaSpec Incorporated
    Inventors: Zhenjun Diwu, Jianheng Zhang, Yi Tang, Xiang Guobing
  • Patent number: 8093231
    Abstract: Sulfonylethyl and thioethyl phosphorodiamidates, their preparation and intermediates in their preparation, formulations containing them, and their pharmaceutical use. The compounds are useful for treating cancer, alone and in combination with other anticancer therapies.
    Type: Grant
    Filed: July 17, 2007
    Date of Patent: January 10, 2012
    Assignee: Telik, Inc.
    Inventors: David R. Allen, Wenli Ma, Brian T. Peterson, Louise Robinson, Steven R. Schow, Songyuan Shi, Reyna J. Simon, Kevin T. Weber, Michael M. Wick
  • Patent number: 8093285
    Abstract: This application discloses aminopiperidinyl compounds of generic Formulae I-II: or pharmaceutically acceptable salts thereof, wherein m, r, Q1, Q2, Q3, R, Ra, R1, R2a, R2b, and R3 are defined as described herein, useful for treatment of diseases associated with monoamine reuptake inhibitors. Also provided are pharmaceutical compositions, methods of using, and methods of preparing the compounds.
    Type: Grant
    Filed: March 25, 2009
    Date of Patent: January 10, 2012
    Assignee: Roche Palo Alto LLC
    Inventors: Pravin Iyer, Matthew C. Lucas, Ryan Craig Schoenfeld, Robert James Weikert
  • Patent number: 8093274
    Abstract: The present invention is directed to novel compounds. These compounds can be useful in inhibiting the activity of GGTase I. The compounds can also be used as anti-cancer therapeutics including as part of methods for treating cancer, in assays, and in kits.
    Type: Grant
    Filed: March 22, 2007
    Date of Patent: January 10, 2012
    Assignee: The Regents of the University of California
    Inventors: Fuyuhiko Tamanoi, Ohyun Kwon, Masaru Watanabe, Hannah Fiji
  • Patent number: 8093264
    Abstract: The invention relates to the inhibition of VEGF receptor signaling and HGF receptor signaling. The invention provides compounds of general formula (A) wherein A1 is sulfur, A3 is CH, A2 is CH, D is heterocycle, Z is oxygen, SO0-2 or NR, Ar is phenyl and G is not a ring, and methods for inhibiting VEGF receptor signaling and HGF receptor signaling. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.
    Type: Grant
    Filed: May 19, 2006
    Date of Patent: January 10, 2012
    Assignee: Methylgene Inc.
    Inventors: Oscar Mario Saavedra, Stephen William Claridge, Lijie Zhan, Franck Raeppel, Arkadii Vaisburg, Stephane Raeppel, Michael Mannion, Frederic Gaudette, Ljubomir Isakovic, Marie-Claude Granger, Naomy Bernstein
  • Patent number: 8088805
    Abstract: The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.
    Type: Grant
    Filed: March 16, 2007
    Date of Patent: January 3, 2012
    Assignee: MethylGene Inc.
    Inventors: Daniel Delorme, Silvana Marcela Leit de Moradei, Sylvie Frechette
  • Patent number: 8088817
    Abstract: A compound represented by the following formula (1) or a salt thereof: The compound has an inhibitory activity on the production of interleukin-6, and is therefore useful as a therapeutic agent for a disease associated with interleukin-6, ocular inflammatory diseases and the like. In the formula, R1 represents a halogen atom, a hydrogen atom, a lower alkyl group which may have a substituent, a formyl group, or a lower alkylcarbonyl group which may have a substituent, R2 represents a bicyclic hydrocarbon group which may have a substituent or a bicyclic heterocyclic group which may have a substituent, R3 represents a hydrogen atom, a lower alkyl group which may have a substituent, an aryl group which may have a substituent, or an acyl group.
    Type: Grant
    Filed: August 25, 2009
    Date of Patent: January 3, 2012
    Assignee: Santen Pharmaceutical Co., Ltd.
    Inventors: Kenji Kawashima, Noriko Kawashima, Hiroshi Enomoto, Minoru Yamamoto, Masaaki Murai
  • Patent number: 8088921
    Abstract: The present invention describes a method for the synthesis of enantiomerically pure 3-amidinophenylalanine derivatives, which are used as pharmaceutically effective urokinase inhibitors, by starting from 3-cyanophenylalanine derivatives. The methods of manufacture comprising only one synthesis step lead to new intermediates, namely 3-hydroxyamidino- and 3-amidrazonophenylalanine derivatives. These intermediates or their acetyl derivatives can be reduced into the desired 3-amidino-phenylalanine derivatives under gentle conditions (H2 or ammonium formiate, Pd/C (approx. 10%), ethanol/water, room temperature, normal pressure or also H2, Pd/C, AcOH or HCl/ethanol, 1-3 bar) in excellent yields and in an enantiomeric excess of up to 99.9%.
    Type: Grant
    Filed: October 15, 2010
    Date of Patent: January 3, 2012
    Assignee: Wilex AG
    Inventors: Hugo Ziegler, Peter Wikstroem
  • Patent number: 8084487
    Abstract: The present invention relates to a process for the production of carbamic acid (2-chloroethyl)(3-oxocyclohexyl)-alkyl ester enantiomers and of 1-carbalkoxy-4-ketoperhydroindole enantiomers.
    Type: Grant
    Filed: August 10, 2009
    Date of Patent: December 27, 2011
    Assignee: Novartis AG
    Inventors: Ernst Kuesters, Murat Acemoglu, Philipp Lustenberger, Gottfried Sedelmeier, Beat Schmitz, Gerhard Penn
  • Patent number: 8080548
    Abstract: The present embodiments are related to the compound of Formula 1 or Formula 2 below and pharmaceutical formulations thereof as well as treatments for a wide variety of Central Nervous System disorders with the pharmaceutical formulations. Some embodiments include the use of a variety of the instant compounds which surprisingly and advantageously exhibit improved pharmacokinetic and therapeutic profiles in comparison to pivagabine.
    Type: Grant
    Filed: August 10, 2009
    Date of Patent: December 20, 2011
    Assignee: Cenerx Biopharma, Inc.
    Inventor: Michael Rafferty
  • Patent number: 8076487
    Abstract: A pyridone derivative represented by Formula [1] or an agriculturally acceptable salt thereof: wherein R1 is a C1-6 alkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, or the like; R2 and R3 are each independently a hydrogen atom, a nitro group, a cyano group, or the like; and A is a group represented by Formula A-1, Formula A-2, Formula A-3, Formula A-4, or Formula A-5: The compounds represented by general formula [1] control various weeds growing in upland fields, orchards, paddy fields, and non-crop lands while showing high safety to useful plants and crops.
    Type: Grant
    Filed: January 31, 2007
    Date of Patent: December 13, 2011
    Assignees: Kumiai Chemical Industry Co., Ltd., Ihara Chemical Industry Co., Ltd.
    Inventors: Fumiaki Takabe, Shunichirou Fukumoto, Ryu Kajiki, Sohei Asakura, Ryohei Ueno, Masami Kobayashi, Satoru Takahashi, Norihisa Yonekura, Ryo Hanai, Takashi Mitsunari
  • Patent number: 8076494
    Abstract: Disclosed is a process for the manufacture of a compound of formula (I) wherein Hal represents fluoro or chloro, and R1 and R2 represent, independently from one another, hydrogen or Hal; in which process a compound of formula (II) is converted to a corresponding alkyl, fluoroalkyl or aryl sulfonic acid ester, which is then reacted with an alkali metal nitrite in the presence of a suitable crown ether in a polar non-nucleophilic solvent at a temperature of ?10 to 50° C. to give the compound of formula (I).
    Type: Grant
    Filed: August 31, 2010
    Date of Patent: December 13, 2011
    Assignee: Basilea Pharmaceutica AG
    Inventors: Marc Muller, Lin Xu
  • Patent number: 8071796
    Abstract: The current invention describes novel chiral synthetic routes and intermediates for the manufacture of chiral anti-inflammatory agents of general formula VIII in which at least one of the groups X1, X2, X3 is selected from fluoro, chloro, bromo, hydroxy, methoxy, ethoxy, trifluoromethyl, amino whereas the other groups X1, X2, X3 have the meaning of a hydrogen atom, in which at least one of the groups Z1, Z2, Z3 is selected from —O—, —S—, —NH—, —N(—CH3)—, whereas the other groups Z1, Z2, Z3 have the meaning of a —CH2— group, and in which Ar is an aromatic group.
    Type: Grant
    Filed: April 17, 2008
    Date of Patent: December 6, 2011
    Assignee: Intendis GmbH
    Inventors: Steffen Schweizer, Alfred Olbrich
  • Patent number: 8071388
    Abstract: The invention provides compositions and methods for the detection of biological targets, (e.g. nucleic acids and proteins) by nucleic acid-templated chemistry, for example, by generating fluorescent polymethine dyes.
    Type: Grant
    Filed: February 24, 2009
    Date of Patent: December 6, 2011
    Assignee: Ensemble Therapeutics Corporation
    Inventors: Yumei Huang, James M. Coull
  • Patent number: 8071582
    Abstract: The present invention relates to novel aniline derivatives and their use in therapy, in particular their use in the treatment of fungal infections.
    Type: Grant
    Filed: January 13, 2010
    Date of Patent: December 6, 2011
    Assignee: UCB Pharma S.A.
    Inventors: Andrew David Carr, Judi Charlotte Neuss, Michael Glen Orchard, David William Porter
  • Patent number: 8071637
    Abstract: The present invention provides dithiolopyrrolone compounds of the general formula I, and their salts, wherein A is sulfur or carbon, and R1, R2, and R3 are selected from groups defined herein, and wherein when A is sulfur, then B is oxygen, and n=1 or 2, and when A is carbon, then B is oxygen or sulfur, and n=1. The compounds are useful for the prevention and treatment of microbial infections such as HIV infection, and for the treatment of blood disorders, such as neutropenia. In particular, the compounds are useful for the manufacture of medicaments for increasing white blood cells.
    Type: Grant
    Filed: September 10, 2007
    Date of Patent: December 6, 2011
    Assignee: Welichem Biotech Inc.
    Inventors: Yingping Guo, Genhui Chen, Bin Li